# US 2019/0314428 A1 · Methods and compositions for changing the composition of the skin microbiome using complex mixtures of bacterial strains

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314428 A1
- Document ID: US20190314428A1
- Status: Published application
- Kind: A1
- Application number: 16/343,277
- Filed: 2017-10-19
- Published: 2019-10-17
- Earliest claimed: 2016-10-19
- Assignees: S-Biomedic NV
- Applicants: S-Biomedic NV
- Inventors: Bernhard Pätzold; Marc Güell
- Web page: https://patentgrep.com/patent/US20190314428A1

## CPC

- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 38/011: {from plants}
- A61K 38/018: {from milk}
- A61K 47/38: Cellulose; Derivatives thereof
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/08: Antiseborrheics
- A61P 17/10: Anti-acne agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Aspects of the invention relate to compositions comprising two or more live bacterial strains for topical administration to the skin, wherein the two or more live bacterial strains are Propionibacterium acnes (P. acnes) bacterial strains, and methods for use.

## Claims

### Claim 1

A composition for topical administration to the skin comprising a live Propionibacterium acnes (P. acnes) bacterial strain, wherein the live P. acnes bacterial strain is a P. acnes single-locus sequence typing (SLST) type K8 strain, and wherein the composition further comprises one or more of a thickener, buffer, or carrier.

### Claim at position 2

-7. (canceled)

### Claim 8 (depends on 1)

The composition of claim 1, wherein the thickener comprises hydroxyethyl cellulose, starch, gum, kaolin, hydrated aluminum silicate, fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose, ethylene glycol monostearate, or sodium alginate.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the hydroxyethyl cellulose comprises NATROSOL® hydroxyethylcellulose (HEC).

### Claim 10 (depends on 1)

The composition of claim 1, wherein the concentration of the thickener is from about 1%-5%.

### Claim at position 6

-12. (canceled)

### Claim 13 (depends on 1)

The composition of claim 1, wherein the composition further comprises a P. acnes SLST type C3 strain.

### Claim at position 8

-15. (canceled)

### Claim 16 (depends on 1)

The composition of claim 1, wherein the composition includes at least 104 colony-forming units per milliliter (CFU/ml) of the live P. acnes bacterial strain.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The composition of claim 1, wherein the composition is in the form of a gel, cream, ointment lotion, or powder and/or wherein the composition is part of a two-component dispensing system.

### Claim 19 (depends on 1)

The composition of claim 1, further comprising an additional P. acnes bacterial strain selected from the group consisting of: D1, H1, H2, H3, K1, K2, K4, K6, K9, and L1 SLST type strains.

### Claim at position 13

-52. (canceled)

### Claim 53 (depends on 1)

The composition of claim 1, wherein the composition does not include a ribotype 6 (RT6) strain of P. acnes.

### Claim 54 (depends on 1)

The composition of claim 1, wherein the composition does not include a Phylotype III strain of P. acnes.

### Claim 55 (depends on 1)

The composition of claim 1, wherein the composition is stable at room temperature for at least three months.

### Claim 56 (depends on 1)

The composition of claim 1, wherein the composition is not naturally occurring.

### Claim 57 (depends on 1)

A method comprising administering the composition of claim 1 to a subject, optionally wherein the subject is a human subject.

### Claim 58 (depends on 57)

The method of claim 57, wherein the method comprises improving the appearance of the skin and/or maintaining healthy skin.

### Claim 59 (depends on 57)

The method of claim 57, wherein the method comprises treating or preventing a condition selected from the group consisting of: acne, oily skin, progressive macular hypomelanosis, dandruff, atopic eczema, atopic dermatitis and rosacea.

### Claim 60 (depends on 57)

The method of claim 57, wherein the method comprises administering the composition to a subject who also receives or has previously received treatment with a disinfectant or an antibiotic.

### Claim 61

A kit comprising a container housing freeze-dried live bacteria, wherein the freeze-dried live bacteria comprise a Propionibacterium acnes (P. acnes) single-locus sequence typing (SLST) type K8 strain.

### Claim 62 (depends on 61)

The kit of claim 61, wherein the kit further comprises a disinfectant or antibiotic.

### Claim 63 (depends on 61)

The kit of claim 61, wherein the kit further comprises a P. acnes SLST type C3 strain.

### Claim 64

A composition for topical administration to the skin comprising two or more different live Propionibacterium acnes (P. acnes) bacterial strains, wherein the live P. acnes single-locus sequence typing (SLST) type K8 strain and a live P. acnes SLST type C3 strain, optionally wherein the composition further comprises one or more of a thickener, buffer, or carrier.
